Selatogrel is under clinical development by Idorsia Pharmaceutical and currently in Phase III for ... Idorsia’s pipeline includes various drugs for the treatment of fabry disease, pediatric insomnia, ...
Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...
Methods: Data from medical records of the 44 heterozygous females followed at Cedars-Sinai Medical Center were compiled and analyzed for symptoms of Fabry disease. Quality of life data were also ...
We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...
Pablo Legorreta, CEO, highlighted strong 2024 performance, with Portfolio Receipts reaching $2.8 billion, at the high end of guidance and representing 13% growth in Royalty Receipts. He noted this ...
Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.
PC hardware is nice, but it’s not much use without innovative software. I’ve been reviewing software for PCMag since 2008, and I still get a kick out of seeing what's new in video and photo ...
The past two years have been punishing for the biotech and pharma space. As Wall Street chased the artificial-intelligence boom, drugmakers were left behind, with pharma stocks trading at a ...
Picture Tree Intl. has acquired international sales rights for “Prank,” a family adventure-comedy directed by Benjamin Heisenberg (“The Robber”), who co-wrote the script with Peer Klehmet ...
Spinal Muscular Atrophy (SMA), Gaucher’s Disease, Pompe Disease, Fabry Disease, Narcissistic Personality Disorder (NPD), and Alkaptonuria, or Black Urine Disease.
Jackson Mahomes’ appearance at Super Bowl 2025 to watch his brother — and Chiefs star quarterback — Patrick Mahomes included a stop for a photo with President Donald Trump, according to a ...